Featured Articles

Time Intervals Until the First Return Office Visit After New Medications

By December 15, 2020No Comments

Featured Article

Featured Article

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

Read more

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

Heather Onorati

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

In patients with acne, atopic dermatitis and psoriasis, specifically, poor adherence to topical treatments has been a common challenge, according to studies. One reported reason is dissatisfaction with treatment efficacy. Closing the gap between prescription and follow-up visit may encourage patients to fill prescriptions sooner; initial efficacy may motivate further compliance, according to the study.

“Shortening the time to the first return visit may make doing the treatment appear to be less burdensome,” write Steven R. Feldman, M.D., Ph.D., and colleagues.

The group analyzed data representing 10.9 million estimated visits that were logged in the National Ambulatory Medical Care Survey and represented diagnoses for acne, atopic dermatitis and psoriasis between the years 2014 and 2016, which was the most recent available data. The time to a first return visit for patients with acne, atopic dermatitis and psoriasis who were prescribed at least one new medication was often more than two months regardless of whether they were prescribed a new medication.

Whether reasons for scheduling long intervals are due to tradition or unawareness of more optimal timeframes is not well known, the authors write.

Previous studies have indicated that adherence increases around the time of an office visit and then decreases rapidly in the days afterward, they note. Physicians may be able to use this tendency to create accountability for patients to begin and continue treatments.

“If a decreased interval between office visits can improve initial adherence, patients may see greater efficacy when using medications and be encouraged to continue their treatments,” the authors write.

While in-person follow-up visits may not be feasible for all patients due to travel distance, cost or other barriers, the authors note other methods of contacting and engaging the patient that have been shown to improve adherence, such as phone calls, emails, text messages and telemedicine visits.

“A lack of accountability may be an underappreciated component of non-adherence,” the authors write. “The timing of return visits may be an important factor to consider … for overcoming the adherence hurdle.”

Read Full Article Now
Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry.
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Dermatological Safety of Cosmetic Products Marketed to Children: Insights on the Sephora Kids Phenomenon

Dermatological Safety of Cosmetic Products Marketed to Children: Insights on the Sephora Kids Phenomenon

| Featured Articles, Latest News, The Latest | No Comments
Harness Klotho Protein’s UV-Defying Power for Breakthrough Photoaging Repair Every day, more families are turning to beauty aisles with their kids in tow, and retailers are responding. Sephora’s new “Kids”…
Journal of Drugs in Dermatology JDD Article About Hypochlorous Acid for a Persistent Filler Nodule: A Case Report

Hypochlorous Acid for a Persistent Filler Nodule: A Case Report

| Case Reports, Featured Articles, Latest News, Medical Derm, The Latest | No Comments
Biofilms, Hard Nodules, and the Surprising Power of Hypochlorous Acid Most hyaluronic acid lumps after filler settle on their own, but a rare “delayed-onset” nodule can spell trouble—especially when it…
Journal of Drugs in Dermatology JDD Interview with Dr. Christopher Bunick: An In-Depth Interview Focusing on Atopic Dermatitis and the LEVEL UP Period 2 Data

JDD Interview with Dr. Christopher Bunick: An In-Depth Interview Focusing on Atopic Dermatitis and the LEVEL UP Period 2 Data

| Atopic Dermatitis, Featured Articles, Latest News, The Latest, Video Pearls | No Comments
Switching from Dupilumab to Upadacitinib: Practice-Informing Evidence from LEVEL UP SWITCH This exclusive video interview with Dr. Christopher Bunick unveils the practice-changing insights of the LEVEL UP SWITCH study, designed…

Leave a Reply